M
IMEPro
J45.20 Respiratory
Updated March 2026

Mild intermittent asthma, uncomplicated

ICD-10 Code: J45.20 · Body Part: Head/Brain (TBI)

QME Evaluation Process

PFTs with bronchodilator response, methacholine challenge if needed, workplace exposure assessment. Chapter 5 respiratory impairment. Evaluate occupational sensitizer or irritant exposure.

Typical Impairment Rating

5-15% WPI

AMA Guides Edition

5th Edition

Common Treatments

+ Rescue inhaler
+ Allergen/irritant avoidance
+ Inhaled corticosteroids if persistent

Related Conditions

Body Part Guide

Head/Brain (TBI) Evaluation Guide

Impairment rating methods, common conditions, and QME evaluation protocols

View Guide →

QME Specialties for Mild intermittent asthma, uncomplicated

Find a QME Specialist

Browse QME-certified physicians who evaluate mild intermittent asthma, uncomplicated and related head/brain (tbi) conditions in California.

Browse Neurology Physicians →

Frequently Asked Questions

What is Mild intermittent asthma, uncomplicated (J45.20)?

Mild intermittent asthma, uncomplicated is an ICD-10 diagnosis code (J45.20) classified under Respiratory conditions. It affects the Head/Brain (TBI) and is commonly encountered in California workers' compensation claims. QME physicians evaluate this condition using AMA Guides 5th Edition protocols.

How is J45.20 rated for impairment?

The typical whole person impairment (WPI) range for Mild intermittent asthma, uncomplicated is 5-15% WPI. The exact rating depends on clinical findings, imaging, and the evaluation method (DRE or ROM) chosen by the QME physician per AMA Guides 5th Edition.

What is the QME evaluation process for J45.20?

PFTs with bronchodilator response, methacholine challenge if needed, workplace exposure assessment. Chapter 5 respiratory impairment. Evaluate occupational sensitizer or irritant exposure.

What treatments are common for Mild intermittent asthma, uncomplicated?

Common treatments for Mild intermittent asthma, uncomplicated include Rescue inhaler, Allergen/irritant avoidance, Inhaled corticosteroids if persistent. Treatment appropriateness and outcomes are considered during the QME evaluation when determining permanent and stationary status and apportionment.